Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N. Jax T, et al. Among authors: von eynatten m. Cardiovasc Diabetol. 2017 Jan 21;16(1):13. doi: 10.1186/s12933-016-0493-3. Cardiovasc Diabetol. 2017. PMID: 28109295 Free PMC article. Clinical Trial.
Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial.
Laakso M, Rosenstock J, Groop PH, Barnett AH, Gallwitz B, Hehnke U, Tamminen I, Patel S, von Eynatten M, Woerle HJ. Laakso M, et al. Among authors: von eynatten m. Diabetes Care. 2015 Feb;38(2):e15-7. doi: 10.2337/dc14-1684. Diabetes Care. 2015. PMID: 25614693 Clinical Trial. No abstract available.
Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Cooper ME, Perkovic V, McGill JB, Groop PH, Wanner C, Rosenstock J, Hehnke U, Woerle HJ, von Eynatten M. Cooper ME, et al. Among authors: von eynatten m. Am J Kidney Dis. 2015 Sep;66(3):441-9. doi: 10.1053/j.ajkd.2015.03.024. Epub 2015 May 7. Am J Kidney Dis. 2015. PMID: 25960304 Free article.
Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial.
Groop PH, Cooper ME, Perkovic V, Sharma K, Schernthaner G, Haneda M, Hocher B, Gordat M, Cescutti J, Woerle HJ, von Eynatten M. Groop PH, et al. Among authors: von eynatten m. Diab Vasc Dis Res. 2015 Nov;12(6):455-62. doi: 10.1177/1479164115579002. Epub 2015 Jul 28. Diab Vasc Dis Res. 2015. PMID: 26224765 Free article. Clinical Trial.
131 results